Lung cancer drug order trial aims to extend life and ease side effects
NCT ID NCT06486142
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial is testing which sequence of EGFR-inhibitor drugs works best for people with advanced EGFR-mutated lung cancer. About 200 participants will receive either a second-generation drug (afatinib or dacomitinib) followed by a third-generation drug (osimertinib), or osimertinib alone. The study measures how long the cancer is controlled, quality of life, and side effects, and also analyzes blood and tumor samples to find markers that could guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EGFR-inhibitors (afatinib, dacomitinib, osimertinib)
- What this could lead to
- If successful, this could identify the best sequence of targeted drugs to control advanced lung cancer longer and improve quality of life.
- What could go wrong
- This is a phase 3 trial, but results may not apply to all patients. Side effects from these drugs can be significant, and the optimal sequence may not clearly outperform current practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Skåne university hospital
RECRUITINGLund, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.